RESUMO
TRIAL REGISTRATION: ClinicalTrials.gov Clinical Trial NCT00594880.
Assuntos
Terapia Antirretroviral de Alta Atividade , Células Epiteliais/metabolismo , Infecções por HIV/metabolismo , HIV-1/fisiologia , Mucosa Intestinal/metabolismo , Proteína 3 Induzida por Fator de Necrose Tumoral alfa/metabolismo , Adulto , Animais , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/virologia , Feminino , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , HIV-1/efeitos dos fármacos , Humanos , Intestinos/efeitos dos fármacos , Intestinos/virologia , Masculino , Camundongos , Pessoa de Meia-Idade , Proteína 3 Induzida por Fator de Necrose Tumoral alfa/genética , Carga ViralRESUMO
The gastrointestinal (GI) tract harbors most of the body's immune cells and is also a major HIV reservoir in ART-treated patients. To achieve a cure, most HIV-infected cells must be identified and eliminated. While obtaining gut biopsies is a relatively noninvasive method of sampling relevant tissue for monitoring HIV activity, immune cell isolation from these limited tissue samples has proven to be challenging. Enzymatic tissue digestion is required for maximal immune cell isolation from gut biopsies. However, these enzymatic digestions can also be detrimental for preservation of cellular surface markers that are required for accurate identification of various subsets of leukocytes. In this study, we describe an optimized protocol for isolation of lymphocytes from human gut biopsies. We also discuss our validation results, which show that compared with several other collagenase preparations, the use of CSLPA maintains high lymphocyte recovery while preserving the integrity of most cellular surface antigens that we tested. Importantly, chemokine receptors that are used to characterize various subsets of T cells, which are notorious for being digested during a typical enzymatic tissue digestion, are highly preserved using this protocol.
Assuntos
Linfócitos T CD4-Positivos/imunologia , Separação Celular/métodos , Trato Gastrointestinal/imunologia , Infecções por HIV/imunologia , Biópsia/métodos , Contagem de Linfócito CD4 , Quimiocinas/análise , Trato Gastrointestinal/virologia , HIV-1/imunologia , HumanosRESUMO
Many HIV-infected individuals on antiretroviral therapy (ART) exhibit persistent systemic inflammation, which predicts morbidity and mortality. ART-treated subjects concurrently exhibit marked compositional alterations in the gut bacterial microbiota and the degree of dysbiosis correlates with systemic inflammation. Whether interventions to modulate the microbiome can affect systemic inflammation is unknown. An open-label fecal microbial transplantation (FMT) was delivered by colonoscopy to asymptomatic HIV-infected ART-suppressed individuals without antibiotic pre-treatment. Stool was assessed before and after FMT for engraftment of donor microbes, and peripheral blood was assayed for immune activation biomarkers. Six participants received FMT and 2 participants served as controls. No serious adverse effects occurred during 24 weeks of follow-up. At baseline, HIV-infected individuals exhibited microbiota profiles distinct from uninfected donors. During the 8 weeks post-FMT, recipients demonstrated partial engraftment of the donor microbiome (P < 0.05). Recipient microbiota remained significantly distant from donors, unlike that observed following FMT for treatment of C. difficile infection. Systemic inflammatory markers showed no significant change post-FMT. FMT was well-tolerated in ART-treated, HIV-infected individuals. Engraftment was detectable but modest, and appeared to be limited to specific bacterial taxa. Whether antibiotic conditioning can enhance engraftment and the capacity of microbiota to modulate inflammation remains to be investigated.